AU2014304930B2 - Antibody binding sites specific for EGFRvIII - Google Patents

Antibody binding sites specific for EGFRvIII Download PDF

Info

Publication number
AU2014304930B2
AU2014304930B2 AU2014304930A AU2014304930A AU2014304930B2 AU 2014304930 B2 AU2014304930 B2 AU 2014304930B2 AU 2014304930 A AU2014304930 A AU 2014304930A AU 2014304930 A AU2014304930 A AU 2014304930A AU 2014304930 B2 AU2014304930 B2 AU 2014304930B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
egfrviii
chain domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014304930A
Other languages
English (en)
Other versions
AU2014304930A1 (en
Inventor
Kristina Ellwanger
Ivica FUCEK
Stefan Knackmuss
Melvyn Little
Vera MOLKENTHIN
Uwe Reusch
Eugene Zhukovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of AU2014304930A1 publication Critical patent/AU2014304930A1/en
Application granted granted Critical
Publication of AU2014304930B2 publication Critical patent/AU2014304930B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2014304930A 2013-08-07 2014-08-07 Antibody binding sites specific for EGFRvIII Active AU2014304930B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13179630.2 2013-08-07
EP13179630 2013-08-07
EP13189599.7 2013-10-21
EP13189599 2013-10-21
PCT/EP2014/002177 WO2015018527A1 (en) 2013-08-07 2014-08-07 ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII

Publications (2)

Publication Number Publication Date
AU2014304930A1 AU2014304930A1 (en) 2016-02-25
AU2014304930B2 true AU2014304930B2 (en) 2019-11-21

Family

ID=51453717

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014304930A Active AU2014304930B2 (en) 2013-08-07 2014-08-07 Antibody binding sites specific for EGFRvIII

Country Status (13)

Country Link
US (1) US10273309B2 (enExample)
EP (1) EP3030581B1 (enExample)
JP (1) JP6529498B2 (enExample)
CN (1) CN105555804B (enExample)
AU (1) AU2014304930B2 (enExample)
CA (1) CA2920173C (enExample)
DK (1) DK3030581T3 (enExample)
HR (1) HRP20210561T1 (enExample)
HU (1) HUE054057T2 (enExample)
LT (1) LT3030581T (enExample)
RU (1) RU2696892C2 (enExample)
SI (1) SI3030581T1 (enExample)
WO (1) WO2015018527A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
CA2968510C (en) * 2014-11-25 2020-11-03 Pharmabcine Inc. Novel egfrviii antibody and composition comprising same
HK1253512A1 (zh) 2015-05-29 2019-06-21 Amphivena Therapeutics, Inc. 双特异性cd33和cd3结合蛋白质的使用方法
IL281396B (en) 2015-06-09 2022-07-01 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
EP3310811B1 (en) * 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
BR112018014585A2 (pt) 2016-01-21 2018-12-11 Pfizer receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
AR107582A1 (es) 2016-02-03 2018-05-16 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
RU2721582C1 (ru) * 2016-08-05 2020-05-20 И-Байолоджикс Инк. Антитела против лиганда-1 запрограммированной смерти (PD-L1) и их применение
KR102048476B1 (ko) 2016-08-05 2019-11-26 주식회사 와이바이오로직스 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
CN106501518A (zh) * 2017-01-06 2017-03-15 北京弘润天源生物技术股份有限公司 一种检测EGFRvⅢ的免疫组化抗体试剂及检测方法
WO2018158349A1 (en) * 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
WO2019175368A1 (en) * 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
SG11202102859TA (en) * 2018-12-21 2021-04-29 Hoffmann La Roche Antibodies binding to cd3
US20230192805A1 (en) * 2019-01-14 2023-06-22 Nanjing Legend Biotech Co., Ltd. Chimeric receptor polypeptides and uses thereof
CR20220330A (es) 2019-12-13 2022-08-04 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso.
EP4545569A3 (en) * 2020-06-30 2025-10-08 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
US20240101646A1 (en) * 2021-01-22 2024-03-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
WO2023287941A2 (en) * 2021-07-16 2023-01-19 Medical Guidance Systems, Llc Anti-tax interacting protein-1 (tip1) binding molecules
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
CN120303301A (zh) * 2022-10-11 2025-07-11 艾比欧公司 表皮生长因子受体变体iii抗体
CN121399157A (zh) 2023-06-12 2026-01-23 美国安进公司 淋巴毒素β受体激动剂结合蛋白

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457586A1 (en) * 2003-06-27 2012-05-30 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
YU63302A (sh) * 2000-02-25 2005-09-19 The Government Of The Un.Stat. Anti-egfrv iii scfvs sa pojačanom citotoksičnošću i povećanim prinosom, imunotoksini na bazi istog i metodi za upotrebu na bazi istog
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457586A1 (en) * 2003-06-27 2012-05-30 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B. D. CHOI ET AL, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2012-12-17), vol. 110, no. 1, doi:10.1073/pnas.1219817110, ISSN 0027-8424, pages 270 - 275 *

Also Published As

Publication number Publication date
BR112016002610A8 (pt) 2018-01-23
RU2016106577A (ru) 2017-09-14
BR112016002610A2 (pt) 2017-09-12
CN105555804B (zh) 2020-12-25
WO2015018527A1 (en) 2015-02-12
DK3030581T3 (da) 2021-04-12
LT3030581T (lt) 2021-05-25
JP6529498B2 (ja) 2019-06-12
HK1218552A1 (zh) 2017-02-24
US20160152728A1 (en) 2016-06-02
CA2920173C (en) 2021-08-10
RU2696892C2 (ru) 2019-08-07
HRP20210561T1 (hr) 2021-05-14
EP3030581A1 (en) 2016-06-15
HUE054057T2 (hu) 2021-08-30
SI3030581T1 (sl) 2021-07-30
US10273309B2 (en) 2019-04-30
AU2014304930A1 (en) 2016-02-25
CA2920173A1 (en) 2015-02-12
CN105555804A (zh) 2016-05-04
JP2016536322A (ja) 2016-11-24
EP3030581B1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
JOP20200237B1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TW201613973A (en) Bispecific CD33 and CD3 binding proteins
MX2020004410A (es) Anticuerpos biespecificos con funciones efectoras reducidas.
WO2021022304A3 (en) Bispecific anti lrrc15 and cd3epsilon antibodies
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EP4417263A3 (en) Cd3 binding antibodies
MX2017015380A (es) Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33.
WO2013188693A8 (en) Antigen binding constructs to cd3
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
NZ731633A (en) Antibodies against cd73 and uses thereof
EP3954713A3 (en) Bispecific antibodies that bind to cd38 and cd3
MY197218A (en) Multispecific antigen-binding molecules and uses thereof
MX2018010776A (es) Moleculas de union de antigeno multiespecificas y usos de las mismas.
AU2014287011A8 (en) Bispecific CD3 and CD19 antigen binding constructs
EP3766903A3 (en) Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases
BR112016002610A2 (pt) anticorpo de ligação a locais específicos para egfrviii
AR121863A2 (es) Proteínas biespecíficas de unión a cd33 y cd3
HK1236413A1 (en) Bispecific cd33 and cd3 binding proteins
EA202090303A2 (ru) Композиции антител для лечения опухолей
AR099798A1 (es) Métodos y composiciones de anticuerpos para el tratamiento de tumores

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)